IngredientsTrillium chloropetalum, also known as giant trillium, giant wakerobin, or common trillium, is a species of flowering plant in the family Melanthiaceae. It is classified in the family Melanthiaceae, order Liliales, and belongs to the subgenus Sessilia, which comprises the sessile-flowered trilliums.
A closely related variety, Trillium chloropetalum var. giganteum, was originally described as Trillium giganteum by Hooker and Arnott in 1841 before being subsumed under T. chloropetalum. Among its varieties, Trillium chloropetalum var. giganteum bears an epithet from the Latin giganteus (giant-like), highlighting its notably larger flowers and overall stature compared to the type variety. The species was originally described as a variety of Trillium sessile, with the basionym Trillium sessile var. chloropetalum Torr.
In 1856, John Torrey described Trillium sessile var. chloropetalum based on a specimen collected by John Milton Bigelow two years earlier in the "redwoods" of California. At the time, Bigelow was exploring the valleys and tributaries of the Sacramento and San Joaquin rivers, but the precise original location of his specimen remains unknown. In 1903, Thomas Jefferson Howell described the species Trillium chloropetalum based on Torrey's variety.
Across traditional and herbal literature, the broader genus Trillium is associated with an array of common names. These include bethroot, birthroot, cough root, great white trillium, ground lily, Indian balm, Jew's harp, purple trillium, red trillium, snake bite, stinking Benjamin, trillium, wake-robin, and white wake-robin. The epithet chloropetalum derives from the Greek chloros ("green") and pétalon ("petal"), as the petals are occasionally green in some populations.
Trillium chloropetalum is a perennial herbaceous plant species characterized by its erect stem reaching 20–70 cm tall, three sessile ovate leaves in a whorl, and a solitary, sessile flower with three green sepals and three petals varying from yellow-green to pink or dark purple. Trillium chloropetalum is a perennial, clump-forming herbaceous plant with a thick underground rhizome. It is one of the largest of all Trillium species, with a scape (stem) from 20 to 70 cm (7.9 to 27.6 in) long.
Like all trilliums, it has a whorl of three bracts (leaves) and a single trimerous flower with 3 sepals, 3 petals, two whorls of 3 stamens each, and 3 carpels fused into a single ovary with 3 stigmas. The bracts are broadly ovate, 7 to 21 cm long and 7 to 18 cm wide, usually with brownish mottling but sometimes unmottled. This species exhibits high morphological variability, particularly in petal color, with populations often displaying multiple shades within the same area, and it produces a pulpy, red-purple berry-like fruit containing numerous seeds.
Endemic to California, it thrives in moist, shaded environments such as redwood forest edges, chaparral, and canyon banks at elevations of 100–2000 m, blooming from April to May with a sweet, rose-like fragrance. It is endemic to the western U.S. state of California, being especially frequent in and around the San Francisco Bay Area. Distributed primarily along the North and Central Coast Ranges and the San Francisco Bay region, from Monterey County northward to Mendocino County and extending into the Sierra Nevada.
The medicinal and phytochemical literature on "giant trillium" must be understood within the broader genus context. The genus Trillium consists of 31 species, widely distributed from the western Himalayas to Japan, China, Kamchatka (Russia) and North America, and is an important source of bioactive compounds of different classes like steroids, glycosides, terpenoids, sterols, saponins, sapogenins and flavonoids. Most published pharmacological research focuses on closely related species — particularly T. govanianum, T. tschonoskii, T. erectum, and T. grandiflorum — rather than T. chloropetalum specifically. Different trillium species contain slightly different chemical profiles. The Himalayan species Trillium govanianum has been studied more intensively than its North American relatives because of its prominence in traditional South Asian medicine.
Historically, the subterranean rhizome, or rootstock, was the primary part of the plant valued for its properties. In herbal practice, the root (technically the rhizome) is the part most commonly used. It is typically dried and prepared as a tincture, a decoction simmered in water, or ground into a powder for topical poultices.
The leaves have been used as a potherb or salad green in some traditional contexts, though this is rare in contemporary practice. The leaves were also boiled in lard and applied to ulcers as a poultice, and to prevent gangrene, according to historical Eclectic medical references. Topical preparations have been used to relieve insect bites and skin irritations.
Trillium, a genus of perennial wildflowers, is known by common names like Wake-robin and Birthroot, and has a long history as a medicinal plant in North America. The most significant traditional application of Trillium centered on women's reproductive health, which is the origin of the plant's common name, Birthroot. Various Trillium species have been used by American Indians to treat gynecological conditions (including irregular menstrual periods, menstrual pain, and excessive vaginal discharge) and to aid childbirth (hence the name birthroot).
Trillium root was used to facilitate childbirth, and to treat other female problems by the women of many Native American tribes. Trillium root was considered to be a sacred female herb and they only spoke of it to their medicine women. Native American tribes and early American settlers utilized the rootstock as a uterine tonic and as a partus preparator to assist in childbirth. The plant was administered as a tea or decoction to facilitate labor.
For the California-endemic T. chloropetalum specifically, the Friends of Edgewood Natural Preserve references the Native American Ethnobotany Database as a source for indigenous uses of the species. Many Pacific Northwest tribes (Karok, Lummi, Paiute, and others) have used the juice from the plants as a remedy for boils and sore eyes. A decoction of fresh or dried corms has been used as an eye wash. (This usage is documented for the related Pacific Northwest species T. ovatum.)
Literature studies indicate that plant species of this genus have been extensively used as a remedy for various diseases. For example, T. tschonoskii has been traditionally used in China for at least one thousand years for treatment of neurasthenia, giddiness, headache, removing carbuncles, and ameliorating pains.
The rhizomes of Trillium govanianum have traditionally been used in the Ayurvedic system of medicine to treat inflammation, pain, burn, and reproductive malfunctions. The rhizome of T. govanianum is commonly known as "matar zela" or "teen patra" in Pakistan, and "nag chatri" in India. In folk medicine, T. govanianum is used to cure dysentery and boils, in wound healing, and menstrual and sexual disorders, and as anti-inflammatory and antiseptic agent. The powdered roots are used as body and sexual tonic.
Trillium is a woodland wildflower with a long history as a folk medicine, used primarily for controlling bleeding, easing childbirth, and treating respiratory complaints. Native American and Appalachian communities relied on it for centuries. Trillium was first introduced by Stephen W. Williams in 1820 as a precious plant for further research with unique hemorrhage-reducing, pain-relieving, and sedative properties. Eclectic physicians of the 19th century included trillium rhizome in their formularies. Red bethroots were said to check ordinary epistaxis by merely smelling the freshly-exposed surface of the recent root, and the leaves of the beth plants, boiled in lard, were used in some sections of the country as an application to ulcers, tumors, etc.
Other traditional uses include as an expectorant and for treatment of diarrhea. This action was also the basis for its historic use in diarrhea, though no chemical basis has been identified for its traditional use as an expectorant. Although trillium has a long history of use as an herbal means of controlling postpartum bleeding as well as other uterine bleeding conditions, a clear mechanism for this systemic effect has not been identified.
These applications were based on empirical observation passed down through generations.
Steroids and saponins are the main classes of phytochemicals present in these plants. The chemistry behind trillium's traditional uses comes down to two main classes of compounds: steroidal saponins and steroids. A 2018 review published in the journal Molecules confirmed that these are the dominant phytochemicals across the genus. Previous phytochemical investigations of the genus Trillium have reported the identification of fatty acid esters, saponins, phenolics, terpenoids, flavonoids, and steroids.
To date, more than 30 steroidal saponins have been discovered from Trillium species, and they were found to exhibit anti-oxidant, anti-fungal, anti-inflammatory, and anti-cancer properties. Most of the compounds isolated from the genus Trillium described in the literature are saponins containing mono-, di-, tri-, or tetra-saccharide chains, commonly composed of apiose, arabinose, glucose, rhamnose, and xylose.
Tertiary literature documents a fixed and volatile oil, a saponin (trillarin, which is a diglycoside of diosgenin), a glycoside resembling convallamarin, tannic acid, a resin, and considerable starch. Steroidal saponins (i.e., spirostanol, furostanol) have been identified, some of which may possess cytotoxic, antifungal, antioxidant, and cyclooxygenase-2 (COX-2) inhibitory activities.
Rhizomes of T. govanianum are key material for trade and contain trillarin, which upon hydrolysis yields diosgenin. Increased market demand for T. govanianum at the international level is due to an essential phytosteroid sapogenin — diosgenin (2.5%) — which is an important component of commercial steroids and sex hormones. Contemporary scientific investigation has confirmed the presence of steroidal saponins, such as trillarin and diosgenin, within the Trillium rhizome. These compounds are structurally similar to human hormones and may account for the plant's traditional use in gynecological contexts.
Ecdysteroids are polyhydroxy steroids produced by certain plants including those belonging to the genus Trillium. Plants containing ecdysteroids possess noticeable pharmacological properties as anabolic, antidiabetic, analgesic, anti-inflammatory, and anthelmintic activities. To date, two phytoecdysteroids have been reported from the rhizomes of T. govanianum, alongside ten steroidal saponins and one trihydrate fatty acid.
The plant also contains flavonoids, which are common antioxidant compounds found in fruits and vegetables, along with a class of hormones called ecdysteroids that play roles in insect biology but may have subtle biological effects in mammals. The genus Trillium is a rich source of bioactive phytochemicals as steroids, saponin derivatives, and flavonoids.
From Trillium govanianum, isolated known compounds include govanoside D, protodioscin, borassoside E, 20-hydroxyecdysone, 5,20-hydroxyecdysone, govanic acid, and diosgenin. Four spirostanol saponins — borassoside E, pennogenin, diosgenin, and govanoside A — have been isolated from T. govanianum. A phytochemical study on the rhizomes of Trillium tschonoskii led to the isolation of fourteen new steroidal saponins, trillitschosides S1–S14, along with ten known analogues.
It has been reported that steroidal saponins are among the major chemical constituents in medicinal preparations responsible for most of the anti-inflammatory and analgesic activities. Recent reports indicate that saponins suppress the expression of iNOS and COX-2, thus resulting in a noticeable lowering of prostaglandin E2 levels.
Pure molecules effectively inhibit the production of cytokines (TNF-α, IL-1β, and IL-6). The NADES (Natural Deep Eutectic Solvent) extract of Trillium saponins exhibited a strong inhibitory effect on the mRNA expression of inflammatory cytokines TNF-α and IL-1β, and a dose-dependent relationship was observed.
Steroidal saponins of Trillium tschonoskii (TTS) can downregulate P-gp expression in R-HepG2 cells, thereby reversing multidrug resistance. To confirm this mechanism, researchers treated tumor-bearing mouse models with TTS. They found that TTS inhibited tumor cell proliferation and enhanced the cytotoxicity of doxorubicin against primary tumors.
The plant may have astringent properties that account for its ability to limit topical bleeding and irritation. The saponins' membrane-disrupting properties are thought to underlie observed surface astringency, though a clear systemic mechanism for the historically described antihemorrhagic effect has not been established.
Saponins are soapy compounds found in many plants. In trillium, they appear to be responsible for the astringent and uterine-stimulating effects that traditional users observed. The structural similarity of trillium saponins to steroidal hormones has been proposed as a possible mechanism for the plant's historically documented effects on uterine contractility, though this has not been established in controlled human trials.
Steroidal compounds and pharmaceutical potential of the genus are reported, but controlled clinical trials on humans are yet to be conducted. High medicinal value and the peculiar biology have made the genus susceptible to several threats. There are no clinical trial data supporting use for any indication. The totality of the evidence base for Trillium — and in particular for T. chloropetalum — consists of in vitro cell studies, preclinical (animal) experiments, and ethnobotanical documentation. Human clinical trials are absent.
Study type and species: Preclinical/in vivo (animal model), conducted on T. govanianum. Trillium govanianum rhizome is used as an analgesic and anti-inflammatory remedy in traditional medicine in northern Pakistan. In an attempt to establish its medicinal value, the present research evaluated the analgesic and anti-inflammatory potential of T. govanianum. The in vivo anti-inflammatory activity of extract and fractions was investigated in the carrageenan-induced paw edema assay. The in vitro suppression of oxidative burst of extract, fractions, and isolated compounds was assessed through luminol-enhanced chemiluminescence assay. The in vivo analgesic activity was assayed in chemical and thermal nociceptive pain models. The crude methanol extract and its solvent fractions showed anti-inflammatory and analgesic responses, exhibited by significant amelioration of paw edema and relief of tonic visceral chemical and acute phasic thermal nociception.
In mice, a methanolic extract of T. govanianum rhizomes and various fractions (i.e., diosgenin, pennogenin, borassoside E) at 50 mg/kg and 100 mg/kg doses exhibited antinociceptive activity comparable to diclofenac sodium (P<0.05 to P<0.001). Results were similar for both tonic visceral and thermal nociception testing. Anti-inflammatory activity has been demonstrated with a T. govanianum rhizome methanol extract as well as a steroidal saponin extracted from T. tschonoskii rhizomes. In a mouse paw edema model, a methanol extract of T. govanianum rhizome and various fractions (i.e., diosgenin, pennogenin, borassoside E) at doses of 50, 100, and 200 mg/kg exhibited acute anti-inflammatory activity comparable to diclofenac sodium.
Evidence strength: Preliminary; in vivo animal data only. No human clinical trials exist. Results cannot be directly extrapolated to T. chloropetalum.
Study type: In vitro cytotoxicity assays. A phytochemical study on the rhizomes of Trillium tschonoskii led to the isolation of fourteen new steroidal saponins. Their structures were established by spectroscopic analyses. All isolated compounds were screened for cytotoxicity against HepG2 cells; the results demonstrated that only the known compounds 21–24 exhibited remarkable cytotoxic activity against HepG2 cells, which was better than the positive control of 5-FU.
Compounds isolated from T. govanianum (trilliumosides K and L) exhibited significant cytotoxic activity against human lung and colon cancer cell lines in a considerable micromolar range. Trilliumoside K showed significant cytotoxicity with IC50 values of 1.83 and 1.85 µM on A-549 (Lung) and SW-620 (Colon) cell lines, whereas the IC50 value against the A-549 cell line of trilliumoside L was found to be 1.79 µM.
Evidence strength: Preliminary; in vitro only. No clinical oncology data. These findings are hypothesis-generating and have not been validated in human subjects.
The saponin glycosides have been shown to have antifungal activity. This finding derives primarily from studies on T. grandiflorum constituents (Hufford et al., 1988, published in the Journal of Natural Products). Evidence strength: In vitro, limited. No human clinical data.
Although trillium has a long history of use as an herbal means of controlling postpartum bleeding as well as other uterine bleeding problems, a clear mechanism for this systemic effect has not been identified. There is no evidence to support the use of trillium for the treatment of snoring. Research reveals no animal or clinical data regarding the use of trillium for any condition. There is no clinical evidence to guide dosage of trillium.
Evidence strength: Absent for clinical validation. Traditional use is extensively documented but has not been subjected to randomized controlled trials or systematic investigation in human populations.
The pharmacological activities of Trillium species reveal that steroidal saponins exhibit various bioactivities, including anticancer, antidiabetic, neuroprotective, anti-aging, and anti-inflammatory effects. Steroidal saponins from Trillium have exhibited in vivo neuroprotective properties, and sapogenin portions are structurally similar to neurosteroids. These findings are at the preclinical stage only.
There is no clinical evidence to guide dosage of trillium. The following preparations and dosage ranges appear in traditional herbal and historical sources only; they do not reflect validated clinical doses.
There are no established safe dosage ranges based on clinical trials, and herbal references vary widely in their recommendations. Without standardized preparations, the actual concentration of active compounds in any given batch of dried root or tincture is unpredictable.
The U.S. Food and Drug Administration (FDA) has not approved Trillium for any medicinal use.
Trillium fruit and roots contain saponins, which if eaten in large quantities, can cause gastrointestinal distress. It is not recommended for consumption due to the potential for toxicity, especially when ingested raw, as the saponins can be highly irritating to the digestive tract. The saponins in trillium can irritate the digestive tract. Traditional preparations sometimes used it deliberately as an emetic, meaning it was strong enough to induce vomiting at higher doses.
Its use is contraindicated during pregnancy due to its traditional role in stimulating uterine activity. Adverse effects (emmenagogue and uterine stimulant) have been documented. When trillium is taken in high doses it can stimulate menstruation or labor, or it may cause nausea or queasiness.
Although not yet clinically observed, trillium could have potential membrane-irritating effects and induce some cardiac activity. This is a theoretical concern based on saponin pharmacology and has not been confirmed in clinical observation.
Steroidal saponins have been identified, some of which may possess cytotoxic, antifungal, antioxidant, and cyclooxygenase-2 (COX-2) inhibitory activities. Given the COX-2 inhibitory activity observed in preclinical models, theoretical interactions with NSAIDs and anticoagulants may warrant caution, though none have been documented in human studies. No drug interactions are well documented.
A significant concern surrounding Trillium is its conservation status, as the plant is exceptionally slow-growing. It takes a single plant between four and seven years to reach maturity and produce its first flower. Because harvesting the entire rhizome destroys the plant, wild collection has led to the depletion of many species across North America. High medicinal value and the peculiar biology have made the genus susceptible to several threats. Several states and federal lands require collection permits, and removing plants from public land without authorization is illegal in many jurisdictions. Trillium chloropetalum is considered "not commercially viable" since it takes as long as 5 years to produce plants of flowering size. One should verify that a nursery offering this plant has indeed propagated it and not dug it from the wild.
Health conditions that Giant trillium may help support.
Body systems that Giant trillium may help support.
Go back